Deep Tech Opportunities Report
For 13 years, DCVC has backed brilliant entrepreneurs who address the hardest, highest-stakes problems in the world.
Recent Posts
News
Latus Bio finds a better way to deliver genes to cells deep in the brain to help patients with neurodegeneration
News
Creyon Bio deal with Lilly brings up to $1 billion in payments for research on RNA-targeting drugs
Snapshot
Kanvas Bio speeds the search for microbiome therapies through industrial-scale imaging of gut and host cells
DCVC closes $700 million+ in new funds for a healthier planet and healthier lives; releases second-annual Deep Tech Opportunities Report and first-annual DCVC Climate Impact Report
Our first dedicated Climate fund and newest DCVC Bio fund are putting deep tech to work
We back entrepreneurs using AI to unlock potential across sectors.
Spotlight
Fervo Energy
Tapping into the heat beneath our feet to provide gigawatts of clean energy
Latus Bio
Finding precisely tuned viral vectors for gene therapy in CNS disorders
Pivot Bio
Reprogramming soil microbes to produce nitrogen sustainably
Relation
Using machine learning to understand the biology underlying disease
01
/ 03
We have more published scientists than MBAs.
Data Collective is built to identify and support the world’s most ambitious company founders.
DCVC and its portfolio companies are immersed in deep tech: dive in here.
Recent Posts
Deep Tech Opportunities Report
DCVC DTOR 2024: Startup thinking will help the defense and security sectors prepare for new threats
News
Latus Bio finds a better way to deliver genes to cells deep in the brain to help patients with neurodegeneration
News
Creyon Bio deal with Lilly brings up to $1 billion in payments for research on RNA-targeting drugs
Snapshot
Kanvas Bio speeds the search for microbiome therapies through industrial-scale imaging of gut and host cells
2024 Deep Tech Opportunities Report
DCVC’s partners share their thoughts on the most compelling areas of prospective deep tech investment in 2024 and beyond.
In the Media
Endpoints News
With a new CEO, oligonucleotide biotech Creyon forges Eli Lilly partnership
Creyon Bio
Endpoints News
Biotech seed rounds sink to lowest level in years as industry slump drags on [Kiersten Stead featured]
Bloomberg
Khosla-Backed Energy Startup Nabs $258 Million to Help Power Data Centers
Axios
Clinical-stage biotech Solu valued at $100M after raising $41M Series A
Solu Therapeutics